On July 18, according to a statement on the official website of British American Tobacco (BAT), BAT announced that its American subsidiary, RJ Reynolds Vapor Company, had received marketing authorization from the U.S. Food and Drug Administration (FDA) for its Vuse Alto line of 7 e-cigarette products.
Following an extensive scientific review, the FDA issued a marketing authorization to R.J. Reynolds Vapor Company on July 18, involving the Vuse Alto Power Unit and six closed, pre-filled, and non-refillable Vuse Alto tobacco-flavored pods.
Renault e-cigarette company's premarket tobacco product application (PMTA) submitted in 2020 included rigorous scientific studies on Vuse Alto. These studies were built upon previous scientific research submitted for Vuse Solo, Vuse Vibe, and Vuse Ciro, which received marketing authorization for their original flavors in October 2021 and May 2022 respectively. The scientific research in these applications indicates that continuing to sell tobacco-flavored products like Vuse Alto, Vuse Vibe, Vuse Ciro, and Vuse Solo is appropriate for protecting public health.
The Chief Executive Officer of British American Tobacco Group, Tadeu Marroco, stated:
We welcome the FDA's approval of the Vuse Alto device and its flavors. This authorization not only reflects our commitment to a variety of approaches but also supports our vision of a 'better tomorrow.' Currently, we have the largest portfolio of e-cigarette market authorizations available in the U.S., which will help us provide more potential reduced-risk product options for adult smokers.
Maroko emphasized that the successful promotion of legal e-cigarette products requires the FDA to take more measures to combat the illegal e-cigarette products market, which often intentionally targets young people. He added, "By providing a variety of potential reduced-risk products for adult smokers, we are taking solid steps towards establishing a smoke-free world.
Despite Vuse Alto devices and their flavors being authorized, British American Tobacco is still actively responding to the Marketing Denial Order (MDO) issued by the FDA in October 2023 against Altomint and Mixed Berry flavors. According to a court order, the FDA's denial order for Altomint products has been stayed, meaning that adult nicotine consumers can still purchase these products.
The British American Tobacco Group stated that they will continue to collaborate with regulatory authorities to ensure the healthy development of the e-cigarette market, while also providing consumers with more legal and safe e-cigarette product options.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
